Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy.

Journal Article (Journal Article;Multicenter Study)

A trial to evaluate the safety and immunogenicity of recombinant modified vaccinia Ankara (MVA) and fowlpox (FP) vectors expressing multiple HIV-1 proteins was conducted in twenty HIV-1 infected youth with suppressed viral replication on HAART. The MVA and FP-based multigene HIV-1 vaccines were safe and well tolerated. Increased frequencies of HIV-1 specific CD4+ proliferative responses and cytokine secreting cells were detected following immunization. Increased frequencies and breadth of HIV-1 specific CD8 T-cell responses were also detected. Plasma HIV-1-specific antibody levels and neutralizing activity were unchanged following vaccination. Poxvirus-based vaccines may merit further study in therapeutic vaccine protocols.

Full Text

Duke Authors

Cited Authors

  • Greenough, TC; Cunningham, CK; Muresan, P; McManus, M; Persaud, D; Fenton, T; Barker, P; Gaur, A; Panicali, D; Sullivan, JL; Luzuriaga, K; Pediatric AIDS Clinical Trials Group P1059 Team,

Published Date

  • December 9, 2008

Published In

Volume / Issue

  • 26 / 52

Start / End Page

  • 6883 - 6893

PubMed ID

  • 18940219

Pubmed Central ID

  • PMC2845914

International Standard Serial Number (ISSN)

  • 0264-410X

Digital Object Identifier (DOI)

  • 10.1016/j.vaccine.2008.09.084


  • eng

Conference Location

  • Netherlands